We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
REZLIDHIA Dr Reddys Laboratories Australia Pty Ltd
Product name
REZLIDHIA
Accepted date
Oct-2025
Active ingredients
olutasidenib
Proposed indication
Rezlidhia (olutasidenib) is proposed for the treatment of adults who have acute myeloid leukaemia (a type of blood cancer) that has relapsed or has not improved with other treatments, and who have a specific change (mutation) in a gene called IDH1.
Application type
A (new medicine)
Publication date
Oct-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.